# AtriCure to Announce Second Quarter 2026 Financial Results
Canonical URL: https://biopharmsignal.com/news/ATRC/atricure-to-announce-second-quarter-2026-financial-results-ccf9a74f
Ticker: ATRC
Company: AtriCure
Source: AtriCure
Published: 2026-07-02 12:00 EST
Original Source URL: https://ir.atricure.com/news-releases/news-release-details/atricure-announce-second-quarter-2026-financial-results
## Summary

MASON, Ohio --(BUSINESS WIRE)--Jul. 2, 2026-- AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter

## Article Body
MASON, Ohio --(BUSINESS WIRE)--Jul. 2, 2026-- AtriCure, Inc. ( Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its second quarter
## Recent Company News
- 2026-07-02 12:00 EST — [AtriCure to Announce Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/ATRC/atricure-to-announce-second-quarter-2026-financial-results-ccf9a74f) — Source: AtriCure
- 2026-06-25 13:46 EST — [AtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference](https://biopharmsignal.com/news/ATRC/atricure-to-participate-in-the-goldman-sachs-47th-annual-global-health-care-conference) — Source: AtriCure
- 2026-06-25 13:46 EST — [AtriCure Receives CE-Mark for the EnCompass® Clamp](https://biopharmsignal.com/news/ATRC/atricure-receives-ce-mark-for-the-encompassr-clamp) — Source: AtriCure
- 2026-06-25 13:46 EST — [AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Results](https://biopharmsignal.com/news/ATRC/atricure-reports-fourth-quarter-2024-and-full-year-2024-financial-results) — Source: AtriCure
- 2026-06-25 13:46 EST — [AtriCure Reports First Quarter 2025 Financial Results](https://biopharmsignal.com/news/ATRC/atricure-reports-first-quarter-2025-financial-results) — Source: AtriCure
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)